Registration statement for proposed Cullgen merger declared effective by the SEC Proposed merger anticipated to close in JuneAs part of proposed merger, Pulmatrix currently intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technologyFRAMINGHAM, Mass., May 15, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of nove ...